The Life Sciences team advised Stilla Technologies, a start-up specializing in high-precision genetic analysis, and the sellers, on the signing of a put option agreement for the acquisition of Stilla Technologies by Bio-Rad, a global leader in life science research and clinical diagnostics products.
The completion of the transaction is subject to the legal requirement to inform and consult the company's employee representative bodies, as well as to obtain necessary regulatory approvals. It is expected to close in the third quarter of 2025.
This operation will allow Bio-Rad to reinforce its expansion strategy in applied research and clinical diagnostics, while covering the full range of digital PCR applications to better meet the evolving needs of customers in genomics research and applied science.
Founded in 2013, Stilla Technologies develops high-precision digital PCR solutions for biological research and in-vitro diagnostics. Its Nio® system integrates instruments, microfluidic cartridges, reagents, and software, using Crystal Digital PCR™ technology from École Polytechnique. It enables ultra-sensitive, multiplexed biomarker analysis, supporting advances in cancer monitoring through liquid biopsies.
The Goodwin team included:
- In Paris, Anne-Charlotte Rivière, Benhouda Derradji and Alex Lecoeur on corporate aspects, Marie Fillon and Louis de Chezelles on IP aspects, and Charles-Henri de Gouvion Saint Cyr and Gauthier Pinabiaux on tax aspects.
- In London, Sarah Jordan, Samuel Honnywill and Anuj Ghai on antitrust regulatory aspects, and Gretchen Scott, Joseph Ndep and Rachel Thurbon on RGPD aspects.
- In Boston, Martin Gomez on IP aspects, and Daniel S. Karelitz on tax aspects.